🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

311 results for “International” Clear

  1. XEN45

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 other completed

    1 trial

  2. ZX008 (Fenfluramine Hydrochloride)

    International Peace Maternity and Child Health Hospital

    Dravet Syndrome

    phase 3 small molecule completed

    1 trial

  3. bimatoprost ophthalmic solution formulation A

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 small molecule terminated

    1 trial

  4. botulinum toxin Type A

    Allergan Pharmaceuticals International Limited

    Pediatrics

    phase 3 mab completed

    4 trials

  5. mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    COVID

    phase 3 small molecule completed

    1 trial

  6. teclistamab, teclistamab, JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  7. -, MERCAPTOPURINE , -, Film-Coated Tablet without JNJ-77242113, JNJ-77242113, AZATHIOPRINE , METHOTREXATE , JNJ-77242113

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  8. A clinical study to evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 other active

    1 trial

  9. A sterile preservative-free solution with identical composition as the drug product, but without the protein.

    Kiniksa Pharmaceuticals International, plc

    Sjögren’s Disease

    phase 2 small molecule active

    1 trial

  10. AGN 211745

    Allergan Pharmaceuticals International Limited

    Choroid Neovascularization

    phase 2 small molecule terminated

    1 trial

  11. AL-335

    Janssen Cilag International NV

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  12. Abiprubart

    Kiniksa Pharmaceuticals International, plc

    Sjögrens Disease

    phase 2 small molecule terminated

    1 trial

  13. Actrapid 100 international units/ml solution for injection in vial, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, SODIUM CHLORIDE, Natriumklorid Fresenius Kabi 9 mg/ml, spädningsvätska för parenteral användning, Albumin Baxalta 200 g/l infusionsvätska, lösning, Glucos Fresenius Kabi 200 mg/ml infusionsvätska, lösning, A24110He

    Lacuna Pharma Pty Ltd

    Moderate to severe hypertriglyceridemia

    phase 2 small molecule active

    1 trial

  14. Apalutamide

    Janssen Cilag International NV

    Salivary Gland Neoplasms

    phase 2 small molecule active

    1 trial

  15. Azacitidine

    Janssen Cilag International NV

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  16. Bivalent killed oral cholera vaccine

    International Peace Maternity and Child Health Hospital

    Cholera

    phase 2 mab active

    1 trial

  17. Brimo PS DDS®

    Allergan Pharmaceuticals International Limited

    Patients Who Participated in an Intravitreal Brimo PS DDS® Study

    phase 2 small molecule completed

    1 trial

  18. CARBOPLATIN , JNJ-42756493, JNJ-63723283, CISPLATIN , JNJ-42756493, JNJ-63723283, JNJ-42756493

    Janssen-Cilag International N.V.

    Metastatic or Locally Advanced Urothelial Cancer

    phase 2 small molecule active

    1 trial

  19. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, JNJ-61186372, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. Cetrelimab

    Janssen Cilag International NV

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  21. Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP, JNJ-64407564, JNJ-64407564, Clonazepam Orally Disintegrating Tablets, USP, Pregabalin-ratiopharm® 25 mg Hartkapseln, Pregabalin-ratiopharm® 50 mg Hartkapseln, Clonazepam Orally Disintegrating Tablets, USP, DEXAMETHASONE ELIXIR, USP, Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 2 small molecule active

    1 trial

  22. DEXAMETHASONE SODIUM PHOSPHATE, VELCADE 3.5 mg powder for solution for injection, DARATUMUMAB, CYCLOPHOSPHAMIDE

    Janssen-Cilag International N.V.

    Amyloid Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  23. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  24. Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Dexamethason 4 mg JENAPHARM®, teclistamab, teclistamab, Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 2 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Pomalidomide, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Im

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources